Fig. 3: MFS after BCR among patients with nmCSPC by PSADT cohort including historical Johns Hopkins data. | Prostate Cancer and Prostatic Diseases

Fig. 3: MFS after BCR among patients with nmCSPC by PSADT cohort including historical Johns Hopkins data.

From: Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment

Fig. 3

Includes historical metastasis-free survival data of patients with BCR after radical prostatectomy from Pound et al. 1999 [3]. The adjusted Cox proportional hazards models adjusted for patient demographics and clinical characteristics including age, age group (<60 [reference], 60–69, 70–79, and ≥80 years), race (White [reference], Black, Hispanic, and other), log(time from definitive therapy to index date), log(index PSA), modified Charlson Comorbidity Index, and index year (2006–2016 vs. 2017–2020). *P-value ≤ 0.05. BCR biochemical recurrence; CI confidence interval; HR hazard ratio; MFS metastasis-free survival; nmCSPC nonmetastatic castration-sensitive prostate cancer; PSA prostate-specific antigen; PSADT PSA doubling time.

Back to article page